Montelair (Montelukast)

Montelukast selectively blocks the CysLT1 receptor, a binding site for cysteinyl leukotrienes. By inhibiting this receptor, the drug prevents leukotriene‑driven bronchoconstriction, mucus production and inflammatory cell recruitment, thereby improving airway patency and reducing allergic symptoms.

The appropriate dose of Montelair is determined by the prescribing healthcare professional based on the patient’s age, weight, indication and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as written.

Montelair is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if clearly needed. The drug is excreted in breast milk; breastfeeding mothers should discuss potential risks with their clinician.

To request Montelair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelair belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who have difficulty using inhalers or need additional control of allergic components of asthma, but it is not a rescue medication.

Montelair should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Montelair is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, although rare, include severe allergic reactions such as rash, angioedema or urticaria, neuropsychiatric effects like depression, agitation or suicidal thoughts, and eosinophilic granulomatosis with polyangiitis. Patients should seek immediate medical attention if any of these occur.

Montelair is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Patients with a history of severe neuropsychiatric disorders should use it with caution, and it should not replace rescue inhalers for acute asthma attacks.